OCUGEN, INC. Liabilities, Fair Value Adjustment
OCUGEN, INC. (OCGN) reported Liabilities, Fair Value Adjustment of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:LiabilitiesFairValueAdjustment · last filed 2022-02-28
- OCUGEN, INC. liabilities, fair value adjustment for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- OCUGEN, INC. liabilities, fair value adjustment for the quarter ending 2020-09-30 was $0.00.
- OCUGEN, INC. liabilities, fair value adjustment for the quarter ending 2020-06-30 was $0.00.
- OCUGEN, INC. liabilities, fair value adjustment for the quarter ending 2020-03-31 was $0.00.
- OCUGEN, INC. liabilities, fair value adjustment for fiscal 2021 was $0.00.
- OCUGEN, INC. liabilities, fair value adjustment for fiscal 2020 was $0.00.
- OCUGEN, INC. liabilities, fair value adjustment for fiscal 2019 was -$3.19M, a 291.45% decline from fiscal 2018.
- OCUGEN, INC. liabilities, fair value adjustment for fiscal 2018 was $1.66M.
| Period end | Liabilities, Fair Value Adjustment 3 month | Liabilities, Fair Value Adjustment 6 month | Liabilities, Fair Value Adjustment 9 month | Liabilities, Fair Value Adjustment 12 month | Liabilities, Fair Value Adjustment 12 month as first filed |
|---|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-28 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 derived: sum of 3 quarters · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 | |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | $16.71M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-14 | $0.00 10-Q · filed 2020-08-14 | $16.71M derived: sum of 3 quarters · filed 2022-02-28 | -$1.80M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-08 | $16.71M derived: sum of 2 quarters · filed 2022-02-28 | -$1.80M derived: sum of 3 quarters · filed 2022-02-28 | -$2.41M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2019-12-31 | $16.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$1.80M derived: sum of 2 quarters · filed 2022-02-28 | -$2.41M derived: sum of 3 quarters · filed 2022-02-28 | -$3.19M 10-K · filed 2022-02-28 | -$3.19M 10-K · filed 2020-03-27 |
| 2019-09-30 | -$18.51M 10-Q · filed 2020-11-06 | -$19.12M derived: sum of 2 quarters · filed 2020-11-06 | -$19.90M 10-Q · filed 2020-11-06 | -$19.44M derived: sum of 4 quarters · filed 2020-11-06 | |
| 2019-06-30 | -$608.15K 10-Q · filed 2020-08-14 | -$1.38M 10-Q · filed 2020-08-14 | -$928.26K derived: sum of 3 quarters · filed 2020-08-14 | $533.61K derived: sum of 4 quarters · filed 2020-08-14 | |
| 2019-03-31 | -$776.27K 10-Q · filed 2020-05-08 | -$320.11K derived: sum of 2 quarters · filed 2020-05-08 | $1.14M derived: sum of 3 quarters · filed 2020-05-08 | $1.13M derived: sum of 4 quarters · filed 2020-05-08 | |
| 2018-12-31 | $456.16K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $1.92M derived: sum of 2 quarters · filed 2020-03-27 | $1.91M derived: sum of 3 quarters · filed 2020-03-27 | $1.66M 10-K · filed 2020-03-27 | |
| 2018-09-30 | $1.46M 10-Q · filed 2019-11-12 | $1.45M derived: sum of 2 quarters · filed 2019-11-12 | $1.21M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | -$8.24K 8-K/A · filed 2019-10-07 | -$253.35K 8-K/A · filed 2019-10-07 | |||
| 2014-12-31 | $7.57M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $10.56M derived: sum of 2 quarters · filed 2016-03-10 | $8.27M derived: sum of 3 quarters · filed 2016-03-10 | $10.01M 10-K · filed 2016-03-10 | |
| 2014-09-30 | $2.99M 10-Q · filed 2015-11-12 | $697.00K derived: sum of 2 quarters · filed 2015-11-12 | $2.44M 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | -$2.29M 10-Q · filed 2015-08-12 | -$551.00K 10-Q · filed 2015-08-12 | |||
| 2014-03-31 | $1.74M 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |